Voyager Therapeutics

Historical price data

Voyager Therapeutics is dedicated to developing transformative gene therapies for neurological disorders by leveraging human genetics and its proprietary TRACER™ capsid discovery platform. The company's strategy combines internal pipeline development with strategic platform collaborations to de-risk R&D and generate non-dilutive funding. Key achievements include the generation of novel, IV-administered capsids with enhanced brain tropism and a pipeline featuring multiple preclinical and IND-enabling programs for high-need conditions like Alzheimer's and ALS.

TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) is a high-throughput, in vivo screening platform that discovers novel AAV capsids capable of crossing the blood-brain barrier and targeting the central nervous system following simple intravenous administration.

Voyager competes with large pharma in Alzheimer's (e.g., Biogen, Lilly), antisense therapy companies in ALS (e.g., Biogen/Ionis), and other biotechs developing novel CNS-tropic AAV capsids. Its differentiation is the TRACER platform's potential for non-invasive, widespread CNS gene delivery.